BIO-key International, Inc. (BKYI) Q4 2022 Earnings Call Transcript

BIO-key International, Inc. (NASDAQ:BKYI) Q4 2022 Earnings Conference Call March 31, 2023 10:00 AM ET

Company Participants

William Jones - Catalyst IR
Michael DePasquale - Chairman and CEO
Galen Rodgers - VP of Channels
Cecilia Welch - CFO

Conference Call Participants

Jack Vander Aarde - Maxim Group

Operator

Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the BIO-key International Fourth Quarter Conference Call. During management's prepared remarks, all participants will be in a listen-only mode. Afterwards, listeners will be invited to participate in a question-and-answer session. As a reminder, this conference is being recorded today, Friday, March 31, 2023.

Now I would like to turn the call over to Bill Jones, Investor Relations. Please proceed.

William Jones

Thank you, thank you for joining todays call. Participating today are BIO-key's Chairman and CEO, Mike DePasquale; CFO, Cecilia Welch. VP of Channels for North America, Galen Rodgers, and myself.

I will remind everyone that today's conference call and webcast as well as answers to questions may include forward-looking statements, which are subject to certain risks and uncertainties that may cause actual results to differ from those projected.

Words such as anticipate, believe, estimate, expect and plan and similar words typically identify and express forward-looking statements. These forward-looking statements are made based on management's beliefs and assumptions today, using information currently available pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.

For a complete description of these and other risk factors that may affect the future performance of BIO-key, please see risk factors in the company's annual report filed on Form 10-K with the Securities and Exchange Commission. Listeners are cautioned not to place undue reliance on such forward-looking statements, which speak only as of today's date. BIO-key company undertakes no obligation to revise or disclose